Note: Additional information will be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis, ACTRIMS, taking place February 22-25, 2023.
CLENE REPORTS NEW DATA FROM THE VISIONARY-MS PHASE 2 STUDY IN MULTIPLE SCLEROSIS DEMONSTRATING CNM-AU8® TREATMENT IMPROVED BRAIN NEURONAL STRUCTURAL INTEGRITY
https://invest.clene.com/news-releas...study-multiple
CLENE REPORTS NEW DATA FROM THE VISIONARY-MS PHASE 2 STUDY IN MULTIPLE SCLEROSIS DEMONSTRATING CNM-AU8® TREATMENT IMPROVED BRAIN NEURONAL STRUCTURAL INTEGRITY
- MRI results reinforce the clinical neurological improvements previously reported
- MRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effect
- MRI results consistently favor CNM-Au8 improvement of neuronal integrity and myelin improvement, showing decreased brain deterioration
- The brain improvements in stable MS patients on background therapy are unprecedented
https://invest.clene.com/news-releas...study-multiple